Author:
Jurowski Kamil,Krośniak Mirosław
Abstract
AbstractChromium, which can currently only be considered pharmacologically active and not an essential element, is a very intriguing elemental impurity in final pharmaceutical products, especially traditional herbal medicinal products. This kind of traditional herbal medicinal product with Marshmallow root (Althaea officinalis L., radix) registered in the EU is widely used among the European population. The aim of this article is to propose a double regulatory strategy in assessing the human health risk of total chromium impurities in cough syrups with Marshmallow Root (Althaea officinalis) available in Polish pharmacies. We applied the strategy based on the requirements of the ICH Q3D (R1) guideline for the assessment of Cr impurities in final traditional herbal medicinal products with Marshmallow Root registered in the EU. Furthermore, we applied the strategy based on the concept of margin of exposure (MoE) considering Cr(VI) genotoxicity mode of action (MOA) and based on BMD10 for Cr(VI) as a point of departure (PoD). The total Cr content was in the range: 1.12–9.61 µg/L (in comparison with the ICH Q3D R1 guidelines: 1100 µg/g). Total Cr levels in a single dose were relatively high compared to raw results, but were not a threat to patients. Comparison of estimated results with oral PDE value for Cr in final drugs suggested by the ICH Q3D R1 guideline (10,700 µg/day) show that all the products analyzed were below this value (the highest result was 278.40 ng/day). Despite conservative assumptions, the MoE values obtained for Cr in daily dose for each Marshmallow Root cough syrup were above 10,000; therefore, exposure to Cr would not cause a health risk for specific population groups (children and adults). It can be summarized that each of the phytopharmaceuticals analysed with Marshmallow root available in Polish pharmacies does not represent a health hazard to patients. We confirm the safety of Cr impurities by applying a double regulatory strategy without the application of an expansive and demanding HPLC-ICP-MS technique for Cr speciation.
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. ICH guideline Q3D (R1) on elemental impurities. 28 March 2019EMA/CHMP/ICH/353369/2013 Committee for Human Medicinal Products (2022, accessed 28 Jan 2022). https://www.ema.europa.eu/en/ich-q3d-elementalimpurities.
2. Vincent, J. B. New evidence against chromium as an essential trace element. J. Nutr. 147(12), 2212–2219. https://doi.org/10.3945/jn.117.255901 (2017).
3. Vincent, J. B. & Brown, S. Introduction: A history of chromium studies (1955–2007). In The Nutritional Biochemistry of Chromium (III) 1–58 (Elsevier, 2019).
4. Rovida, C. et al. Toxicity testing in the 21st century beyond environmental chemicals. Altex 32(3), 171. https://doi.org/10.14573/altex.1506201 (2015).
5. McGovern, T. & Jacobson-Kram, D. Regulation of genotoxic and carcinogenic impurities in drug substances and products. TrAC 25(8), 790–795. https://doi.org/10.1016/j.trac.2006.06.004 (2006).